

# DARZALEX FASPRO®

## CODING & BILLING IN HOSPITAL OUTPATIENT DEPARTMENTS

### Sample CMS-1450 (UB-04) Claim Form

## INDICATIONS

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) is indicated for the treatment of adult patients with multiple myeloma:

- In combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant
- In combination with bortezomib, melphalan, and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant
- In combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy
- In combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant
- In combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor (PI)
- In combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy
- In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy
- As monotherapy in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double refractory to a PI and an immunomodulatory agent

DARZALEX FASPRO® as monotherapy is indicated for the treatment of adult patients with high-risk smoldering multiple myeloma.

## IMPORTANT SAFETY INFORMATION

### CONTRAINDICATIONS

DARZALEX FASPRO® is contraindicated in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase, or any of the components of the formulation.

### WARNINGS AND PRECAUTIONS

#### Hypersensitivity and Other Administration Reactions

Both systemic administration-related reactions, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO®. Fatal reactions have been reported with daratumumab-containing products, including DARZALEX FASPRO®.

Please see Important Safety Information on [pages 5-6](#) and [click here](#) to see the full Prescribing Information.

The information provided is valid as of November 2025 and is subject to change.

CMS, Centers for Medicare & Medicaid Services.

# Checklist for Claims

To potentially avoid delays, underpayments, or denials, it may be helpful to perform a review prior to submitting any claim to a payer.

## THE FOLLOWING MAY BE CONSIDERED:

- Insurance was verified
- This is a covered service
- If required, prior authorization was obtained
- Medical necessity is documented\*
- The correct codes (ICD-10, CPT®, and HCPCS) are reported
- Billed units are accurate and consistent with the code descriptors
- Specific payer requirements were followed

\*A sample letter of medical necessity is available at: [www.JNJwithMe.com/hcp/DARZALEX-FASPRO](http://www.JNJwithMe.com/hcp/DARZALEX-FASPRO).

This document is presented for informational purposes only and is not intended to provide reimbursement or legal advice, nor does it promise or guarantee coverage, levels of reimbursement, payment, or charge. Similarly, all CPT® and HCPCS codes are supplied for informational purposes only and represent no statement, promise, or guarantee by Johnson & Johnson that these codes will be appropriate or that reimbursement will be made. It is not intended to increase or maximize reimbursement by any payer. Laws, regulations, and policies concerning reimbursement are complex and are updated frequently. While we have made an effort to be current as of the issue date of this document, the information may not be as current or comprehensive when you view it. We strongly recommend you consult the payer organization for its reimbursement policies.

CPT® only copyright 2025 American Medical Association. All rights reserved.



**Consult local payers for coding policies, or call a J&J withMe Care Navigator at 833-565-9631, Monday–Friday, 8:00 AM to 8:00 PM ET**

CPT®, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification.

## DARZALEX Faspro® Hospital Outpatient Department Sample Claim Form: CMS-1450 (UB-04)

**A** **Locator Box 42** - List revenue codes in ascending order.

**B** **Locator Box 43** - Enter narrative description for corresponding revenue code.  
Note: If the NDC is required, it will be entered in Locator Box 43.

**C** **Locator Box 44** - Indicate appropriate CPT®, HCPCS codes, and modifiers, as required by payer.

### DARZALEX Faspro®

- **J9144** - Injection, daratumumab, 10 mg and hyaluronidase-fihj
- **JZ modifier** - no discarded amount from a single-dose container

### Drug Administration

- **96401** - Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic

**D** **Locator Box 46** - Enter the units for items/services provided.

### DARZALEX Faspro®

- **J9144** - Enter the amount of drug in HCPCS units according to the drug-specific descriptor and dose: 10 mg, 1 unit; each 1,800 mg dose of DARZALEX Faspro®, 180 units

### Drug Administration

- **96401** - Enter 1 unit

**E** **Locator Box 67** - Indicate diagnosis using appropriate ICD-10-CM codes. Code to the highest level of specificity for the date of service, and enter diagnoses in priority order.

ICD-10 Diagnosis Codes* for Consideration	<b>C90.00</b>	Multiple myeloma not having achieved remission
	<b>C90.01</b>	Multiple myeloma in remission
	<b>C90.02</b>	Multiple myeloma in relapse
	<b>D47.2</b>	Monoclonal gammopathy of undetermined significance (MGUS)

\*These codes are not intended to be promotional or to encourage or suggest use of a drug that is inconsistent with FDA-approved use. The codes provided are not intended to be exhaustive, and depending on the patient, additional codes may apply.

The fact that a drug, device, procedure, or service is assigned an HCPCS code and a payment rate does not imply coverage by the Medicare and/or Medicaid program but indicates only how the product, procedure, or service may be paid if covered by the program. Fiscal Intermediaries (FIs)/Medicare Administrative Contractors (MACs) and/or state Medicaid administration determine whether a drug, device, procedure, or other service meets all program requirements for coverage.

CPT® only copyright 2025 American Medical Association. All rights reserved.

CMS, Centers for Medicare & Medicaid Services; CPT®, Current Procedural Terminology; FDA, U.S. Food and Drug Administration; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; NDC, National Drug Code.

# DARZALEX FASPRO® CMS-1450 (UB-04) Sample Claim Form

1 Anytown Hospital 123 Any Street Anytown, AS 12345		2 Pay-to-name Pay-to-address Pay-to-city/state		3a PAT CONT #1 b MED RES #1 c FED TAX NO. 010001010		4 TYPE OF BILL DOE 1234-97 STATEMENT COVERS PERIOD FROM THROUGH	
8 PATIENT NAME a John B Doe		9 PATIENT ADDRESS b Anytown		c AS		d 12345	
10 BIRTHDATE 07 01 50		11 SEX M		12 DATE 12 13 14		13 TYPE 15 GPO	
14 DHR		15 DHR		16 DHR		17 DHR	
18 DHR		19 DHR		20 DHR		21 DHR	
22 DHR		23 DHR		24 DHR		25 DHR	
26 DHR		27 DHR		28 DHR		29 DHR	
30 DHR		31 DHR		32 DHR		33 DHR	
34 DHR		35 DHR		36 DHR		37 DHR	
38 DHR		39 DHR		40 DHR		41 DHR	
42 DHR		43 DHR		44 DHR		45 DHR	
46 DHR		47 DHR		48 DHR		49 DHR	
50 DHR		51 DHR		52 DHR		53 DHR	
54 DHR		55 DHR		56 DHR		57 DHR	
58 DHR		59 DHR		60 DHR		61 DHR	
62 DHR		63 DHR		64 DHR		65 DHR	
66 DHR		67 DHR		68 DHR		69 DHR	
70 DHR		71 DHR		72 DHR		73 DHR	
74 DHR		75 DHR		76 DHR		77 DHR	
78 DHR		79 DHR		80 DHR		81 DHR	
82 DHR		83 DHR		84 DHR		85 DHR	
86 DHR		87 DHR		88 DHR		89 DHR	
90 DHR		91 DHR		92 DHR		93 DHR	
94 DHR		95 DHR		96 DHR		97 DHR	
98 DHR		99 DHR		100 DHR		101 DHR	
102 DHR		103 DHR		104 DHR		105 DHR	
106 DHR		107 DHR		108 DHR		109 DHR	
110 DHR		111 DHR		112 DHR		113 DHR	
114 DHR		115 DHR		116 DHR		117 DHR	
118 DHR		119 DHR		120 DHR		121 DHR	
122 DHR		123 DHR		124 DHR		125 DHR	
126 DHR		127 DHR		128 DHR		129 DHR	
130 DHR		131 DHR		132 DHR		133 DHR	
134 DHR		135 DHR		136 DHR		137 DHR	
138 DHR		139 DHR		140 DHR		141 DHR	
142 DHR		143 DHR		144 DHR		145 DHR	
146 DHR		147 DHR		148 DHR		149 DHR	
150 DHR		151 DHR		152 DHR		153 DHR	
154 DHR		155 DHR		156 DHR		157 DHR	
158 DHR		159 DHR		160 DHR		161 DHR	
162 DHR		163 DHR		164 DHR		165 DHR	
166 DHR		167 DHR		168 DHR		169 DHR	
170 DHR		171 DHR		172 DHR		173 DHR	
174 DHR		175 DHR		176 DHR		177 DHR	
178 DHR		179 DHR		180 DHR		181 DHR	
182 DHR		183 DHR		184 DHR		185 DHR	
186 DHR		187 DHR		188 DHR		189 DHR	
190 DHR		191 DHR		192 DHR		193 DHR	
194 DHR		195 DHR		196 DHR		197 DHR	
198 DHR		199 DHR		200 DHR		201 DHR	
202 DHR		203 DHR		204 DHR		205 DHR	
206 DHR		207 DHR		208 DHR		209 DHR	
210 DHR		211 DHR		212 DHR		213 DHR	
214 DHR		215 DHR		216 DHR		217 DHR	
218 DHR		219 DHR		220 DHR		221 DHR	
222 DHR		223 DHR		224 DHR		225 DHR	
226 DHR		227 DHR		228 DHR		229 DHR	
230 DHR		231 DHR		232 DHR		233 DHR	
234 DHR		235 DHR		236 DHR		237 DHR	
238 DHR		239 DHR		240 DHR		241 DHR	
242 DHR		243 DHR		244 DHR		245 DHR	
246 DHR		247 DHR		248 DHR		249 DHR	
250 DHR		251 DHR		252 DHR		253 DHR	
254 DHR		255 DHR		256 DHR		257 DHR	
258 DHR		259 DHR		260 DHR		261 DHR	
262 DHR		263 DHR		264 DHR		265 DHR	
266 DHR		267 DHR		268 DHR		269 DHR	
270 DHR		271 DHR		272 DHR		273 DHR	
274 DHR		275 DHR		276 DHR		277 DHR	
278 DHR		279 DHR		280 DHR		281 DHR	
282 DHR		283 DHR		284 DHR		285 DHR	
286 DHR		287 DHR		288 DHR		289 DHR	
290 DHR		291 DHR		292 DHR		293 DHR	
294 DHR		295 DHR		296 DHR		297 DHR	
298 DHR		299 DHR		300 DHR		301 DHR	
302 DHR		303 DHR		304 DHR		305 DHR	
306 DHR		307 DHR		308 DHR		309 DHR	
310 DHR		311 DHR		312 DHR		313 DHR	
314 DHR		315 DHR		316 DHR		317 DHR	
318 DHR		319 DHR		320 DHR		321 DHR	
322 DHR		323 DHR		324 DHR		325 DHR	
326 DHR		327 DHR		328 DHR		329 DHR	
330 DHR		331 DHR		332 DHR		333 DHR	
334 DHR		335 DHR		336 DHR		337 DHR	
338 DHR		339 DHR		340 DHR		341 DHR	
342 DHR		343 DHR		344 DHR		345 DHR	
346 DHR		347 DHR		348 DHR		349 DHR	
350 DHR		351 DHR		352 DHR		353 DHR	
354 DHR		355 DHR		356 DHR		357 DHR	
358 DHR		359 DHR		360 DHR		361 DHR	
362 DHR		363 DHR		364 DHR		365 DHR	
366 DHR		367 DHR		368 DHR		369 DHR	
370 DHR		371 DHR		372 DHR		373 DHR	
374 DHR		375 DHR		376 DHR		377 DHR	
378 DHR		379 DHR		380 DHR		381 DHR	
382 DHR		383 DHR		384 DHR		385 DHR	
386 DHR		387 DHR		388 DHR		389 DHR	
390 DHR		391 DHR		392 DHR		393 DHR	
394 DHR		395 DHR		396 DHR		397 DHR	
398 DHR		399 DHR		400 DHR		401 DHR	
402 DHR		403 DHR		404 DHR		405 DHR	
406 DHR		407 DHR		408 DHR		409 DHR	
410 DHR		411 DHR		412 DHR		413 DHR	
414 DHR		415 DHR		416 DHR		417 DHR	
418 DHR		419 DHR		420 DHR		421 DHR	
422 DHR		423 DHR		424 DHR		425 DHR	
426 DHR		427 DHR		428 DHR		429 DHR	
430 DHR		431 DHR		432 DHR		433 DHR	
434 DHR		435 DHR		436 DHR		437 DHR	
438 DHR		439 DHR		440 DHR		441 DHR	
442 DHR		443 DHR		444 DHR		445 DHR	
446 DHR		447 DHR		448 DHR		449 DHR	
450 DHR		451 DHR		452 DHR		453 DHR	
454 DHR		455 DHR		456 DHR		457 DHR	
458 DHR		459 DHR		460 DHR		461 DHR	
462 DHR		463 DHR		464 DHR		465 DHR	
466 DHR		467 DHR		468 DHR		469 DHR	
470 DHR		471 DHR		472 DHR		473 DHR	
474 DHR		475 DHR		476 DHR		477 DHR	
478 DHR		479 DHR		480 DHR		481 DHR	
482 DHR		483 DHR		484 DHR		485 DHR	
486 DHR		487 DHR		488 DHR		489 DHR	
490 DHR		491 DHR		492 DHR		493 DHR	
494 DHR		495 DHR		496 DHR		497 DHR	
498 DHR		499 DHR		500 DHR		501 DHR	
502 DHR		503 DHR		504 DHR		505 DHR	
506 DHR		507 DHR		508 DHR		509 DHR	
510 DHR		511 DHR		512 DHR		513 DHR	
514 DHR		515 DHR		516 DHR		517 DHR	
518 DHR		519 DHR		520 DHR		521 DHR	
522 DHR		523 DHR		524 DHR		525 DHR	
526 DHR		527 DHR		528 DHR		529 DHR	
530 DHR		531 DHR		532 DHR		533 DHR	
534 DHR		535 DHR		536 DHR		537 DHR	
538 DHR		539 DHR		540 DHR		541 DHR	
542 DHR		543 DHR		544 DHR		545 DHR	
546 DHR		547 DHR		548 DHR		549 DHR	
550 DHR		551 DHR		552 DHR		553 DHR	
554 DHR		555 DHR		556 DHR		557 DHR	
558 DHR		559 DHR		560 DHR		561 DHR	
562 DHR		563 DHR		564 DHR		565 DHR	
566 DHR		567 DHR		568 DHR		569 DHR	
570 DHR		571 DHR		572 DHR		573 DHR	
574 DHR		575 DHR		576 DHR		577 DHR	
578 DHR		579 DHR		580 DHR		581 DHR	
582 DHR		583 DHR		584 DHR		585 DHR	
586 DHR		587 DHR		588 DHR		589 DHR	
590 DHR		591 DHR		592 DHR		593 DHR	
594 DHR		595 DHR		596 DHR		597 DHR	
598 DHR		599 DHR		600 DHR		601 DHR	
602 DHR		603 DHR		604 DHR		605 DHR	
606 DHR		607 DHR		608 DHR		609 DHR	
610 DHR		611 DHR		612 DHR		613 DHR	
614 DHR		615 DHR		616 DHR		617 DHR	
618 DHR		619 DHR		620 DHR		621 DHR	
622 DHR		623 DHR		624 DHR		625 DHR	
626 DHR		627 DHR		628 DHR		629 DHR	
630 DHR		631 DHR		632 DHR		633 DHR	
634 DHR		635 DHR		636 DHR		637 DHR	
638 DHR		639 DHR		640 DHR		641 DHR	
642 DHR		643 DHR		644 DHR		645 DHR	
646 DHR		647 DHR		648 DHR		649 DHR	
650 DHR		651 DHR		652 DHR		653 DHR	
654 DHR		655 DHR		656 DHR		657 DHR	
658 DHR		659 DHR		660 DHR		661 DHR	
662 DHR		663 DHR		664 DHR		665 DHR	
666 DHR		667 DHR		668 DHR		669 DHR	
670 DHR		671 DHR		672 DHR		673 DHR	
674 DHR		675 DHR		676 DHR		677 DHR	
678 DHR		679 DHR		680 DHR		681 DHR	
682 DHR		683 DHR		684 DHR		685 DHR	
686 DHR		687 DHR		688 DHR		689 DHR	
690 DHR		691 DHR		692 DHR		693 DHR	
694 DHR		695 DHR		696 DHR		697 DHR	
698 DHR		699 DHR		700 DHR		701 DHR	
702 DHR		703 DHR		704 DHR		705 DHR	
706 DHR		707 DHR		708 DHR		709 DHR	
710 DHR		711 DHR		712 DHR		713 DHR	
714 DHR		715 DHR		716 DHR		717 DHR	
718 DHR		719 DHR		720 DHR		721 DHR	
722 DHR		723 DHR		724 DHR		725 DHR	
726 DHR		727 DHR		728 DHR		729 DHR	
730 DHR		731 DHR		732 DHR		733 DHR	
734 DHR		735 DHR		736 DHR		737 DHR	
738 DHR		739 DHR		740 DHR		741 DHR	
742 DHR		743 DHR		744 DHR		745 DHR	
746 DHR		747 DHR		748 DHR		749 DHR	
750 DHR		751 DHR		752 DHR		753 DHR	
754 DHR		755 DHR		756 DHR		757 DHR	
758 DHR		759 DHR		760 DHR		761 DHR	
762 DHR		763 DHR		764 DHR		765 DHR	
766 DHR		767 DHR		768 DHR		769 DHR	
770 DHR		771 DHR		772 DHR		773 DHR	
774 DHR		775 DHR		776 DHR		777 DHR	
778 DHR		779 DHR		780 DHR			

## IMPORTANT SAFETY INFORMATION (cont'd)

### WARNINGS AND PRECAUTIONS (cont'd)

#### *Systemic Reactions*

In a pooled safety population of 1446 patients with multiple myeloma (N=1235) or light chain (AL) amyloidosis (N=193) who received DARZALEX FASPRO® as monotherapy or as part of a combination therapy, 7% of patients experienced a systemic administration-related reaction (Grade 2: 3%, Grade 3: 0.8%, Grade 4: 0.1%). In patients with high-risk smoldering multiple myeloma (N=193), systemic administration-related reactions occurred in 17% of patients in AQUILA (Grade 2: 7%, Grade 3: 1%).

In all patients (N=1639), systemic administration-related reactions occurred in 7% of patients with the first injection, 0.5% with the second injection, and cumulatively 1% with subsequent injections. The median time to onset was 3.2 hours (range: 4 minutes to 3.5 days). Of the 283 systemic administration-related reactions that occurred in 135 patients, 240 (85%) occurred on the day of DARZALEX FASPRO® administration. Delayed systemic administration-related reactions have occurred in 1% of the patients.

Severe reactions included hypoxia, dyspnea, hypertension, tachycardia, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma. Other signs and symptoms of systemic administration-related reactions may include respiratory symptoms, such as bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritus, chills, vomiting, nausea, hypotension, and blurred vision.

Pre-medicate patients with histamine-1 receptor antagonist, acetaminophen, and corticosteroids. Monitor patients for systemic administration-related reactions, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) administration-related reactions, immediately and permanently discontinue DARZALEX FASPRO®. Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO® depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions.

Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with daratumumab-containing products. If ocular symptoms occur, interrupt DARZALEX FASPRO® and seek immediate ophthalmologic evaluation prior to restarting DARZALEX FASPRO®.

#### *Local Reactions*

In this pooled safety population of 1446 patients with multiple myeloma (N=1253) or light chain amyloidosis (N=193), injection-site reactions occurred in 8% of patients, including Grade 2 reactions in 1.1%. The most frequent (>1%) injection-site reactions were injection site erythema and injection site rash. In patients with high-risk smoldering multiple myeloma (N=193), injection-site reactions occurred in 28% of patients, including Grade 2 reactions in 3%. These local reactions occurred a median of 6 minutes (range: 0 minutes to 6.5 days) after starting administration of DARZALEX FASPRO®. Monitor for local reactions and consider symptomatic management.

#### **Infections**

DARZALEX FASPRO® can cause serious, life-threatening, or fatal infections. In patients who received DARZALEX FASPRO® in a pooled safety population including patients with smoldering multiple myeloma and light chain (AL) amyloidosis (N=1639), serious infections, including opportunistic infections, occurred in 24% of patients, Grade 3 or 4 infections occurred in 22%, and fatal infections occurred in 2.5%. The most common type of serious infection reported was pneumonia (8.5%).

Monitor patients for signs and symptoms of infection prior to and during treatment with DARZALEX FASPRO® and treat appropriately. Administer prophylactic antimicrobials according to guidelines.

#### **Neutropenia**

Daratumumab may increase neutropenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX FASPRO® until recovery of neutrophils. In lower body weight patients receiving DARZALEX FASPRO®, higher rates of Grade 3-4 neutropenia were observed.

## IMPORTANT SAFETY INFORMATION (cont'd)

### WARNINGS AND PRECAUTIONS (cont'd)

#### Thrombocytopenia

Daratumumab may increase thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Consider withholding DARZALEX FASPRO® until recovery of platelets.

#### Embryo-Fetal Toxicity

Based on the mechanism of action, DARZALEX FASPRO® can cause fetal harm when administered to a pregnant woman. DARZALEX FASPRO® may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX FASPRO® and for 3 months after the last dose.

The combination of DARZALEX FASPRO® with lenalidomide, thalidomide, or pomalidomide is contraindicated in pregnant women because lenalidomide, thalidomide, and pomalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide, thalidomide, or pomalidomide prescribing information on use during pregnancy.

#### Interference With Serological Testing

Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive indirect antiglobulin test (indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab administration. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum. The determination of a patient's ABO and Rh blood type are not impacted.

Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX FASPRO®. Type and screen patients prior to starting DARZALEX FASPRO®.

#### Interference With Determination of Complete Response

Daratumumab is a human immunoglobulin G (IgG) kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some DARZALEX FASPRO®-treated patients with IgG kappa myeloma protein.

### ADVERSE REACTIONS

In multiple myeloma, the most common adverse reaction ( $\geq 20\%$ ) with DARZALEX FASPRO® monotherapy is upper respiratory tract infection. The most common adverse reactions with combination therapy ( $\geq 20\%$  for any combination) include fatigue, nausea, diarrhea, dyspnea, insomnia, headache, rash, pyrexia, cough, muscle spasms, back pain, vomiting, hypertension, musculoskeletal pain, upper respiratory tract infection, peripheral neuropathy, peripheral sensory neuropathy, constipation, pneumonia, edema, peripheral edema, and anemia.

The most common adverse reactions ( $\geq 20\%$ ) in patients with high-risk smoldering multiple myeloma who received DARZALEX FASPRO® monotherapy are upper respiratory tract infection, musculoskeletal pain, fatigue, diarrhea, rash, sleep disorder, sensory neuropathy, and injection site reactions.

The most common hematology laboratory abnormalities ( $\geq 40\%$ ) with DARZALEX FASPRO® are decreased leukocytes, decreased lymphocytes, decreased neutrophils, decreased platelets, and decreased hemoglobin.

Please [click here](#) to read full Prescribing Information for DARZALEX FASPRO®.

cp-552204v2